Affordable Access

Amelioration of radiation esophagitis by orally administered p53/Mdm2/Mdm4 inhibitor (BEB55) or GS-nitroxide.

Authors
  • Kim, Hyun
  • Bernard, Mark E
  • Epperly, Michael W
  • Shen, Hongmei
  • Amoscato, Andrew
  • Dixon, Tracy M
  • Doemling, Alexander S
  • Li, Song
  • Gao, Xiang
  • Wipf, Peter
  • Wang, Hong
  • Zhang, Xichen
  • Kagan, Valerian E
  • Greenberger, Joel S
Type
Published Article
Journal
In Vivo
Publisher
International Institute of Anticancer Research
Publication Date
Jan 01, 2011
Volume
25
Issue
6
Pages
841–848
Identifiers
PMID: 22021675
Source
Medline
License
Unknown

Abstract

Intraesophageal BEB55 and JP4-039 compared to formulation alone increased survival after single fraction (p=0.0209 and 0.0384, respectively) and four fraction thoracic irradiation (p=0.0241 and 0.0388, respectively). JP4-039 was detected in esophagus, liver, bone marrow, and orthotopic Lewis lung carcinoma (3LL) tumor. There was no significant radiation protection of lung tumors by BEB55 or JP4-039 compared to formulation only as assessed by survival (p=0.3021 and 0.3693, respectively). Thus, BEB55 and JP4-039 safely ameliorate radiation esophagitis in mice.

Report this publication

Statistics

Seen <100 times